Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Simple item page
dc.contributor.authorBoswood, Adrianen
dc.contributor.authorGordon, Sonya G.en
dc.contributor.authorHaggstrom, Jensen
dc.contributor.authorWess, G.en
dc.contributor.authorStepien, R. L.en
dc.contributor.authorOyama, Mark A.en
dc.contributor.authorKeene, Bruce W.en
dc.contributor.authorBonagura, Johnen
dc.contributor.authorMacDonald, Kristin A.en
dc.contributor.authorPatteson, M.en
dc.contributor.authorSmith, S.en
dc.contributor.authorFox, P. R.en
dc.contributor.authorSanderson, Karenen
dc.contributor.authorWoolley, Richarden
dc.contributor.authorSzatmari, Viktoren
dc.contributor.authorMenaut, Pierreen
dc.contributor.authorChurch, Whitney M.en
dc.contributor.authorO'Sullivan, M. Lynneen
dc.contributor.authorJaudon, J-Pen
dc.contributor.authorKresken, Jan-Gerden
dc.contributor.authorRush, J.en
dc.contributor.authorBarrett, K. A.en
dc.contributor.authorRosenthal, S. L.en
dc.contributor.authorSaunders, Ashley B.en
dc.contributor.authorLjungvall, Ingriden
dc.contributor.authorDeinert, Michaelen
dc.contributor.authorBomassi, Ericen
dc.contributor.authorEstrada, Amara H.en
dc.contributor.authorFernandez Del Palacio, Maria J.en
dc.contributor.authorMoise, N. Sydneyen
dc.contributor.authorAbbott, Jonathan A.en
dc.contributor.authorFujii, Yokoen
dc.contributor.authorSpier, Alanen
dc.contributor.authorLuethy, Michael W.en
dc.contributor.authorSantilli, Roberto A.en
dc.contributor.authorUechi, Masamien
dc.contributor.authorTidholm, Annaen
dc.contributor.authorSchummer, Christophen
dc.contributor.authorWatson, P.en
dc.date.accessioned2019-08-05T17:19:28Zen
dc.date.available2019-08-05T17:19:28Zen
dc.date.issued2018-01en
dc.description.abstractBackground: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly. Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. Results: At day 35, heart size had reduced in the pimobendan group: median change in (D) LVIDDN -0.06 (IQR: -0.15 to +0.02), P < 0.0001, and LA: Ao -0.08 (IQR: -0.23 to +0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in DLVIDDN was 1.26, P - 0.0003. Hazard ratio for a 0.1 increase in DLA: Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo.en
dc.description.notesThis project was funded by Boehringer Ingelheim Animal Health GmbH. A representative of Boehringer Ingelheim Animal Health GmbH read the final draft before submission. Christoph Schummer and Philip Watson are employees of Boehringer Ingelheim Animal Health GmbH. All other authors have received funding from Boehringer Ingelheim Animal Health GmbH within the last 5 years for some or all of the following activities: research, travel, speaking fees, consultancy fees, and preparation of educational materials.en
dc.description.sponsorshipBoehringer Ingelheim Animal Health GmbHen
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1111/jvim.14885en
dc.identifier.eissn1939-1676en
dc.identifier.issn0891-6640en
dc.identifier.issue1en
dc.identifier.pmid29214723en
dc.identifier.urihttp://hdl.handle.net/10919/92744en
dc.identifier.volume32en
dc.language.isoenen
dc.publisherAmerican College of Veterinary Internal Medicineen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectCardiologyen
dc.subjectCardiovascularen
dc.subjectEchocardiographyen
dc.subjectEndocardiosisen
dc.subjectHeart Failureen
dc.subjectMitral regurgitationen
dc.titleLongitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Studyen
dc.title.serialJournal of Veterinary Internal Medicineen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jvim.14885.pdf
Size:
414.56 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Small Animal Clinical Sciences